There were statistically significant differences in age, tumor size, lymph node status, hormone receptor status, somatic BRCA1/2, and other homologous recombination-related gene mutations in the 3 HRD score groups at baseline (P < .05). This evidence concerns the gene BRCA1 and neoplasm.